Virax Biolabs Group Ratios and Metrics

Market cap in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020
Period Ending	Jan '26 Jan 23, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	2020
Market Capitalization	2	5	2	11	-	-	Upgrade
Market Cap Growth	-84.74%	192.29%	-84.34%	-	-	-	Upgrade
Enterprise Value	-1	-2	-4	6	-	-	Upgrade
Last Close Price	0.27	1.14	0.72	6.95	-	-	Upgrade
PS Ratio	694.36	781.84	10.83	1262.87	-	-	Upgrade
PB Ratio	0.34	0.91	0.33	1.21	-	-	Upgrade
P/TBV Ratio	0.39	0.88	0.32	1.21	-	-	Upgrade
EV/Sales Ratio	-	-	-	701.38	-	-	Upgrade
Debt / Equity Ratio	0.11	0.13	0.04	0.02	-	-0.21	Upgrade
Asset Turnover	0	0.00	0.02	0.00	-	3.98	Upgrade
Inventory Turnover	0.27	0.32	1.01	0.44	-	-	Upgrade
Quick Ratio	9.89	6.47	23.01	10.35	0.02	0.02	Upgrade
Current Ratio	11.35	7.27	25.94	10.61	0.04	0.05	Upgrade
Return on Equity (ROE)	-83.82%	-114.47%	-95.98%	-141.63%	-	-	Upgrade
Return on Assets (ROA)	-48.40%	-64.68%	-49.90%	-72.67%	-2453.52%	-1294.67%	Upgrade
Return on Capital Employed (ROCE)	-109.70%	-107.10%	-114.90%	-64.40%	144.90%	77.50%	Upgrade
Earnings Yield	-272.19%	-122.45%	-397.61%	-50.48%	-	-	Upgrade
FCF Yield	-284.69%	-104.40%	-425.13%	-38.66%	-	-	Upgrade
Buyback Yield / Dilution	-70.75%	-85.92%	-88.75%	-11.15%	-297.67%	-130.43%	Upgrade

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q